US Broker Ratings

Outset Medical, Inc. (OM) Investor Outlook: A Compelling 90% Upside Potential

Outset Medical, Inc. (NASDAQ: OM), a trailblazer in the healthcare sector, is capturing investor attention with a promising potential upside of 90.18%, according to recent analyst ratings. As a company..

Chevron Corporation (CVX): Investor Outlook with a 6.97% Upside Potential

Chevron Corporation (NYSE: CVX), a stalwart in the energy sector, stands as one of the largest integrated oil & gas companies globally, with a commanding market capitalization of $317.92 billion...

Olema Pharmaceuticals, Inc. (OLMA): Analyst Ratings Signal 220% Upside Potential

Olema Pharmaceuticals, Inc. (NASDAQ: OLMA) has emerged as a noteworthy player in the biotechnology sector, focusing on the development of innovative therapies for women’s cancers. Based in San Francisco, this..

Senseonics Holdings, Inc. (SENS) Stock Analysis: A 226% Upside Potential in the Innovative Medical Device Sector

Senseonics Holdings, Inc. (NYSE: SENS) has captured investor attention with its pioneering approach in the healthcare industry, specifically within the medical device segment. Specializing in continuous glucose monitoring (CGM) systems,..

Zhengye Biotechnology Holding L (ZYBT) Stock Analysis: A Mixed Bag of Prospects in the Veterinary Vaccine Market

Zhengye Biotechnology Holding L (ZYBT), a company rooted in the healthcare sector, operates primarily within the drug manufacturing industry, focusing on specialty and generic veterinary vaccines. Based in Jilin, China,..

UroGen Pharma Ltd. (URGN): Exploring a 76% Potential Upside in Biotechnology

UroGen Pharma Ltd. (NASDAQ: URGN) is capturing the attention of investors with its promising position in the biotechnology industry, particularly in the field of urothelial and specialty cancers. Based in..

Absci Corporation (ABSI) Stock Analysis: A Biotech Player with 241% Potential Upside

For investors eyeing the biotechnology sector, Absci Corporation (NASDAQ: ABSI) presents a fascinating opportunity. Specializing in AI-driven drug discovery, Absci operates at the intersection of cutting-edge technology and healthcare innovation...

Evolent Health, Inc (EVH) Stock Analysis: Exploring a 59.89% Potential Upside in Health Information Services

Evolent Health, Inc (NYSE: EVH) is making waves in the healthcare industry, specifically within the Health Information Services sector. With a market capitalization of $1.12 billion, this Arlington, Virginia-based company..

Integra LifeSciences Holdings C (IART): Analyzing the Healthcare Device Leader with a 1.24% Upside Potential

Integra LifeSciences Holdings Corporation (NASDAQ: IART), a stalwart in the healthcare sector, specializes in medical devices that cater to a range of surgical and wound care applications. This Princeton, New..

Aurinia Pharmaceuticals Inc (AUPH) Stock Analysis: Strong Buy Ratings Amid Biotech Growth

Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) is making waves in the biotechnology sector with its promising developments in the treatment of autoimmune diseases. Headquartered in Edmonton, Canada, the company is carving..

Pulse Biosciences, Inc (PLSE) Stock Analysis: Exploring a 46% Potential Upside in the Medical Innovation Sector

Pulse Biosciences, Inc. (NASDAQ: PLSE), a cutting-edge player in the healthcare sector, is capturing investor interest with a potential upside of 46.28%, as reflected in its current analyst ratings. Specializing..

The Pennant Group, Inc. (PNTG) Stock Analysis: Exploring a Potential 37% Upside in Healthcare

For investors seeking exposure in the healthcare sector, The Pennant Group, Inc. (NASDAQ: PNTG) presents an intriguing opportunity. With a market capitalization of $847.11 million, Pennant operates in the medical..

Pacira BioSciences, Inc. (PCRX) Stock Analysis: Assessing the 8.45% Upside Potential Amidst Volatile Metrics

Pacira BioSciences, Inc. (NASDAQ: PCRX) operates at the forefront of non-opioid pain management solutions within the healthcare sector. With its innovative product lineup and strategic industry positioning, this specialty drug..

Neogen Corporation (NEOG) Stock Analysis: Exploring a 14.84% Potential Upside Amidst a Challenging Landscape

Neogen Corporation (NASDAQ: NEOG), a key player in the healthcare sector specializing in diagnostics and research, offers a unique investment opportunity despite facing some headwinds. With a market capitalization of..

U.S. Physical Therapy, Inc. (USPH) Stock Analysis: Exploring a Potential 25.98% Upside

For investors seeking opportunities within the healthcare sector, U.S. Physical Therapy, Inc. (NYSE: USPH) presents a compelling case. As a key player in the medical care facilities industry, USPH specializes..

Novavax, Inc. (NVAX) Stock Analysis: Investors Eye 61.71% Potential Upside Amid Volatile Market Conditions

Novavax, Inc. (NASDAQ: NVAX), a healthcare sector heavyweight specializing in biotechnology, is captivating investor attention with its substantial potential upside of 61.71%. This American company has carved a niche in..

Establishment Labs Holdings Inc (ESTA) Stock Analysis: 44.97% Potential Upside Captures Investor Attention

Investors with an eye on the healthcare sector may find Establishment Labs Holdings Inc (NASDAQ: ESTA) an intriguing option, especially given its impressive potential upside of 44.97%. As a prominent..

Harrow, Inc. (HROW) Stock Analysis: Analyst Ratings Signal a Promising 51.12% Upside for Investors

Harrow, Inc. (HROW), a pivotal player in the healthcare sector, is gaining significant attention from investors due to its strong potential for growth. The company, headquartered in Nashville, Tennessee, specializes..

GoodRx Holdings, Inc. (GDRX) Stock Analysis: Navigating a 30% Potential Upside in HealthTech

GoodRx Holdings, Inc. (NASDAQ: GDRX) presents a compelling opportunity for investors seeking exposure in the health information services sector, known for its innovative approach to healthcare costs in the United..

Vera Therapeutics, Inc. (VERA) Stock Analysis: Exploring a Promising 153% Upside Potential

Vera Therapeutics, Inc. (NASDAQ: VERA), a clinical-stage biotechnology company, is catching the eye of investors with its ambitious approach to tackling serious immunological diseases. With a market capitalization of $1.58..

US Broker Ratings

US Broker Ratings

FTSE 100

Funds